Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Nat Rev Cardiol. 2015 May 5;12(8):475–487. doi: 10.1038/nrcardio.2015.64

Table. Cardiovascular Genotype-based Clinical Trials.

Trial TAILOR
PCI		 POPular
Genetics
Study		 COAG EU-PACT Genetic AF
Study Population Post-PCI ACS,
Stable CAD,
STEMI		 Post-PCI, STEMI Any indication for
warfarin initiation		 AF or venous
thromboembolism		 Persistent AF, recent
cardioversion to sinus
Sample Size 5,270 2,700 1,022 455 620
Pharmacogenetic
Marker		 CYP2C19*2 or *3 CYP2C19*2 or *3 CYP2C9 and
VKORC1 		CYP2C9*2 or *3
and VKORC1
(−1639G→A)		 ADRB1 (389 Arg/Arg)
Treatment Arms Genotyping arm
(clopidogrel in WT
+ ticagrelor in
CYP2C19*2 or *3
carriers) vs Non-
genotyping arm
(clopidogrel)		 Genotyping arm
(clopidogrel in WT
+ ticagrelor or
prasugrel in
CYP2C19*2 or *3
carriers) vs non-
genotyping arm
(ticagrelor)		 Genotyping arm
(Warfarin dose
based on genotype
+ clinical variables)
vs non-genotyping
arm (Warfarin dose
based on clinical
variables)		 Genotyping arm
(Warfarin dose
based on genotype
and clinical
variables) vs non-
genotyping arm
(fixed Warfarin
dosing)		 Bucindolol vs Metoprolol
in B1 389 Arg/Arg carriers
Trial Design Pragmatic, open
label, randomized
prospective,
modified-
enrichment
superiority study		 Open label,
randomized,
prospective, non-
inferiority marker-
based strategy study		 Double-blind,
randomized, prospective, marker-based-
strategy superiority
trial		 Pragmatic, single-
blind, randomized,
marker-based
strategy superiority
trial		 Double-blind, 2–arm,
active-controlled,
adaptive–designed,
enriched superiority study
Primary Endpoints Composite of CV
death, stroke, MI,
ST, urgent
revascularization		 Composite of death,
stroke, MI, ST,
urgent revascularization,
major bleeding.		 Percentage of time
in therapeutic INR		 Percentage of time
in therapeutic INR		 Time to first event of
symptomatic AF/atrial
flutter or all-cause
mortality.
Results Currently recruiting Currently recruiting Genotyping guided
dosing not superior
to conventional
warfarin dosing		 Genotyping guided
dosing superior to
conventional fixed
warfarin dosing		 Currently recruiting
References Clinicaltrials.gov:
NCT01742117 		Clinicaltrials.gov:
NCT01761786 		12 13 Clinicaltrials.gov:
NCT01970501